A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

NCT06948422 · Recruiting

Last updated 2026-05-28

This clinical trial is testing the investigational drug orforglipron (LY3502970) in adults with high blood pressure and obesity or overweight to evaluate how the drug is assigned to participants.

Status Recruiting Currently enrolling participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind screening study

Participants 974 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2025-04 · est. completion 2027-09

Where 100 sites · Argentina, China, Czechia, Germany, Greece, India, Japan, Poland, Puerto Rico, Spain, United States

What this study is testing ClinicalTrials.gov NCT06948422 ↗

Description as written by the study sponsor.

The GZPL master protocol will support 2 independent studies, J2A-MC-GZL1 (GZL1) and J2A-MC-GZL2 (GZL2). The purpose of this study is to create a framework to evaluate the safety and efficacy of orforglipron for the treatment of hypertension in participants with obesity or overweight.

Treatments tested

Orforglipron also known as LY3502970 Drug

Administered orally.
Placebo Drug

Administered orally.

Main thing measured	Number of Participants Allocated to Each ISA
Sponsor	Eli Lilly and Company
Conditions studied	Hypertension
GLP-1 drugs	orforglipron

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06948422 ↗